Inherited and acquired risk factors for venous thromboembolism

Seminars in Respiratory and Critical Care Medicine

Volumn 33, Issue 2, 2012, Pages 127-137

  Baglin, Trevor ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

acquired; cancer; deep vein thrombosis; hospital acquired thrombosis; inherited; pregnancy; pulmonary embolus; risk factors; thrombophilia; thrombosis; venous

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ESTROGEN DERIVATIVE; ETHINYLESTRADIOL; MESTRANOL; ORAL CONTRACEPTIVE AGENT;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ARTICLE; CANCER PATIENT; COMORBIDITY; DEEP VEIN THROMBOSIS; ENVIRONMENTAL FACTOR; GENETIC DISORDER; GENOTYPE ENVIRONMENT INTERACTION; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; HYPERCOAGULABILITY; LUNG EMBOLISM; OBESITY; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; SMOKING; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; GENETIC PREDISPOSITION TO DISEASE; HOSPITALIZATION; HUMANS; PULMONARY EMBOLISM; RISK FACTORS; TIME FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84861585584     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1311791     Document Type: Article

References (71)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet: 1999; 353 9159 1167 1173 (Pubitemid 29155221)
2. Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost: 2006; 4 9 1886 1890 (Pubitemid 44226763)
3. Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a 'call to action' for vascular medicine specialists. J Thromb Haemost: 2007; 5 8 1607 1609 (Pubitemid 47091399)
4. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med: 2007; 167 14 1471 1475 (Pubitemid 47124177)
5. Sweetland S, Green J, Liu B., et al. Million Women Study Collaborators Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ: 2009; 339 b4583
6. Tapson VF, Decousus H, Pini M., et al. IMPROVE Investigators Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest: 2007; 132 3 936 945
7. van Boven HH, Vandenbroucke JP, Briët E, Rosendaal FR. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood: 1999; 94 8 2590 2594 (Pubitemid 29477287)
8. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet: 2003; 362 9383 523 526 (Pubitemid 36976716)
9. Iorio A, Kearon C, Filippucci E., et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med: 2010; 170 19 1710 1716
10. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh: 1965; 13 516 530
11. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest: 1981; 68 5 1370 1373 (Pubitemid 12235040)
12. Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest: 1984; 74 6 2082 2088 (Pubitemid 15197352)
13. Bertina RM, Koeleman BP, Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature: 1994; 369 6475 64 67 (Pubitemid 24144355)
14. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood: 1996; 88 10 3698 3703 (Pubitemid 26383091)
15. Reitsma PH, Rosendaal FR. Past and future of genetic research in thrombosis. J Thromb Haemost: 2007; 5 01 264 269 (Pubitemid 46958841)
16. Bucciarelli P, Rosendaal FR, Tripodi A., et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol: 1999; 19 4 1026 1033 (Pubitemid 29177352)
17. De Stefano V, Simioni P, Rossi E., et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica: 2006; 91 5 695 698 (Pubitemid 43799473)
18. Pabinger I, Schneider B.; Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Arterioscler Thromb Vasc Biol: 1996; 16 6 742 748 (Pubitemid 26179362)
19. Vossen CY, Walker ID, Svensson P., et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol: 2005; 25 9 1992 1997 (Pubitemid 41243474)
20. Greaves M, Baglin T. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease annotation. Br J Haematol: 2000; 109 4 699 703 (Pubitemid 30609745)
21. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA: 2005; 293 19 2352 2361 (Pubitemid 40676757)
22. Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica: 2007; 92 8 1107 1114 (Pubitemid 350144218)
23. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol: 2008; 143 3 321 335
24. Coppens M, Reijnders JH, Middeldorp S, Doggen CJ, Rosendaal FR. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost: 2008; 6 9 1474 1477
25. Baglin T. Unraveling the thrombophilia paradox: from hypercoagulability to the prothrombotic state. J Thromb Haemost: 2010; 8 2 228 233
26. Bezemer ID, Bare LA, Doggen CJ., et al. Gene variants associated with deep vein thrombosis. JAMA: 2008; 299 11 1306 1314 (Pubitemid 351439076)
27. van Hylckama Vlieg A, Baglin CA, Bare LA, Rosendaal FR, Baglin TP. Proof of principle of potential clinical utility of multiple SNP analysis for prediction of recurrent venous thrombosis. J Thromb Haemost: 2008; 6 5 751 754 (Pubitemid 351524534)
28. Baglin T, Gray E, Greaves M., et al. British Committee for Standards in Haematology Clinical guidelines for testing for heritable thrombophilia. Br J Haematol: 2010; 149 2 209 220
29. Baglin T. Communicating benefit and risk. Br J Haematol: 2009; 146 1 31 33
30. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost: 2007; 5 4 692 699 (Pubitemid 46563566)
31. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med: 1998; 158 6 585 593 (Pubitemid 28144815)
32. Heit JA, O'Fallon WM, Petterson TM., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med: 2002; 162 11 1245 1248 (Pubitemid 34595030)
33. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA: 2003; 290 14 1868 1874 (Pubitemid 37430603)
34. Sharrock NE, Go G, Mineo R, Harpel PC. The hemodynamic and fibrinolytic response to low dose epinephrine and phenylephrine infusions during total hip replacement under epidural anesthesia. Thromb Haemost: 1992; 68 4 436 441
35. Prins MH, Hirsh J. A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review. Thromb Haemost: 1990; 64 4 497 500
36. Pearse EO, Caldwell BF, Lockwood RJ, Hollard J. Early mobilisation after conventional knee replacement may reduce the risk of postoperative venous thromboembolism. J Bone Joint Surg Br: 2007; 89 3 316 322 (Pubitemid 46563905)
37. Huo MH, Muntz J. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. Clin Ther: 2009; 31 6 1129 1141
38. Goldhaber SZ, Tapson VF.; DVT FREE Steering Committee A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol: 2004; 93 2 259 262 (Pubitemid 38058748)
39. Geerts WH, Bergqvist D, Pineo GF., et al. American College of Chest Physicians Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 6, Suppl 381S 453S (Pubitemid 351894916)
40. Baglin T. Defining the population in need of thromboprophylaxismaking hospitals safer. Br J Haematol: 2010; 149 6 805 812
41. Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis: 1996; 26 2 65 71 (Pubitemid 26139622)
42. Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest: 2000; 118 6 1680 1684 (Pubitemid 32001795)
43. Cohen AT, Alikhan R, Arcelus JI., et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost: 2005; 94 4 750 759 (Pubitemid 41489233)
44. Francis CW. Clinical practice: prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med: 2007; 356 14 1438 1444 (Pubitemid 46562358)
45. Geerts W. Prevention of venous thromboembolism: a key patient safety priority. J Thromb Haemost: 2009; 7 01 1 8
46. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost: 2007; 5 01 246 254 (Pubitemid 46958840)
47. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA: 2005; 293 6 715 722 (Pubitemid 40216041)
48. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med: 2006; 166 4 458 464
49. Prandoni P, Lensing AW, Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood: 2002; 100 10 3484 3488 (Pubitemid 35303914)
50. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood: 2008; 111 10 4902 4907
51. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol: 2006; 194 5 1311 1315
52. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost: 2003; 1 7 1371 1380
53. Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med: 1995; 238 1 31 37
54. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ: 2009; 339 b2890
55. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol: 2007; 139 2 289 296 (Pubitemid 47493087)
56. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol: 2008; 83 2 97 102
57. Douketis J, Tosetto A, Marcucci M., et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ: 2011; 342 d813
58. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ: 2008; 336 7655 1227 1231 (Pubitemid 351809317)
59. Wu O, Robertson L, Langhorne P., et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost: 2005; 94 1 17 25 (Pubitemid 40974700)
60. Miyakis S, Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 2 295 306
61. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood: 2003; 101 5 1827 1832 (Pubitemid 36237580)
62. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA: 2006; 295 9 1050 1057
63. Baglin C, Brown K, Luddington R, Baglin T.; East Anglian Thrombophilia Study Group Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. Br J Haematol: 1998; 100 4 764 768 (Pubitemid 28126112)
64. Kearon C, Julian JA, Kovacs MJ., et al. ELATE Investigators Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood: 2008; 112 12 4432 4436
65. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med: 2006; 166 7 729 736
66. Langlois NJ, Wells PS. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost: 2003; 90 1 17 26 (Pubitemid 36873854)
67. Tormene D, Simioni P, Pagnan A, Prandoni P. The G20210A prothrombin gene mutation: is there room for screening families? J Thromb Haemost: 2004; 2 8 1487 1488 (Pubitemid 40186155)
68. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood: 2005; 105 3 1102 1105 (Pubitemid 40170881)
69. Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med: 2008; 5 5 e97
70. Brown K, Luddington R, Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol: 1998; 103 1 42 44 (Pubitemid 28470797)
71. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med: 2007; 167 5 497 501 (Pubitemid 46425663)